Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ONY604123
- Development stage
- Unknown
- Lead developer
- ONY Biotech
01
Overview
ONY604123 is an investigational drug candidate currently in Phase 2 clinical development by ONY Biotech. It is being developed for the treatment of neonatal respiratory conditions within the field of neonatology. ONY Biotech is a specialty pharmaceutical company focused on therapies for premature infants, most notably known for its FDA-approved surfactant replacement therapy, Infasurf (calfactant). While the specific molecular target, modality, and chemical structure of ONY604123 have not been publicly disclosed in the company's pipeline, its development is centered on addressing unmet needs in the neonatal intensive care unit (NICU) related to respiratory distress and lung health.
Beyond the preview
Go deeper on ONY604123.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ONY604123.